Tiziana Life Sciences Highlighted in Forbes Article
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced its foralumab, the world’s only fully human anti-CD3 monoclonal antibody, highlighted in a FORBES article by William A. Haseltine. Foralumab, currently in clinical development, is designed to treat multiple sclerosis and other neurodegenerative diseases. The article emphasizes foralumab's ability to improve tissue remodeling and immune responses, suggesting it could enhance outcomes for COVID-19 patients as well. Phase 2 trials for non-active SPMS are expected to commence in Q3 2023, marking a significant advancement in the company's immunotherapy pipeline.
- Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development.
- Potential to improve outcomes for COVID-19 patients and multiple sclerosis.
- Phase 2 trials set to begin in Q3 2023 for non-active SPMS.
- None.
Article entitled "New T Cell Antibody Treatment Improves Outcomes For Covid Patients" reviews the company's first in class foralumab, a unique Intranasal monoclonal antibody designed to treat multiple sclerosis and a range of other neurodegenerative diseases
NEW YORK, March 17, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the Company was highlighted in a FORBES article highlighting foralumab, the Company's unique intranasal monoclonal antibody, which is currently in clinical development to treat multiple sclerosis and a range of other neurodegenerative diseases. Foralumab is the world’s only fully human, anti-CD3 mAb in clinical development.
Forbes contributing author, William A. Haseltine, highlighted foralumab in his article entitled "New T Cell Antibody Treatment Improves Outcomes for Covid Patients".
Noted in the article was:
“Foralumab induces many factors that impact improved tissue remodeling, induction of immune cells, and restriction of effector function, improving disease outcomes while fighting the virus to full strength. These benefits are not limited to Covid-19 patients, as similar results were observed in patients with multiple sclerosis.”
“The anti-CD3 monoclonal treatment effectively modulates the T cell inflammatory response by up or downregulating specific gene and protein expressions, resulting in less severe disease. This novel avenue should be further explored, as more drugs with similar mechanisms could prevent the deaths of thousands.”
To access the full Forbes article, please visit the following hyperlink:
About Foralumab
Activated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor, dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets, an effect demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. Intranasal foralumab Phase 2 trials are expected to start in Q3 2023 in patients with non-active SPMS. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of inflammatory human diseases.1
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development and Investor Relations
+44 (0) 207 495 2379
info@tizianalifesciences.com
Investors:
Irina Koffler
LifeSci Advisors, LLC
646.970.4681
ikoffler@lifesciadvisors.com
_________________
1 https://www.pnas.org/doi/10.1073/pnas.2220272120
FAQ
What is foralumab and its significance for Tiziana Life Sciences (TLSA)?
When are the Phase 2 trials for foralumab expected to start?
What does the FORBES article say about foralumab's effectiveness?
How does foralumab work as a treatment method?
